Premium
Recombinant Human Bone Morphogenetic Protein‐2 Potentiates the In Vivo Osteogenic Ability of Marrow/Hydroxyapatite Composites
Author(s) -
Noshi Toshiaki,
Yoshikawa Takafumi,
Dohi Yoshiko,
Ikeuchi Masako,
Horiuchi Katsuhiro,
Ichijima Kunio,
Sugimura Masahito,
Yonemasu Kunio,
Ohgushi Hajime
Publication year - 2001
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2001.025003201.x
Subject(s) - mesenchymal stem cell , osteocalcin , bone morphogenetic protein 2 , in vivo , alkaline phosphatase , bone morphogenetic protein , chemistry , human bone , recombinant dna , bone marrow , composite number , biomedical engineering , materials science , microbiology and biotechnology , in vitro , composite material , immunology , biology , medicine , biochemistry , gene , enzyme
A composite of marrow mesenchymal stem cells (MSCs) and porous hydroxyapatite (HA) has bone‐forming capability. To promote the capability, we added recombinant human bone morphogenetic protein‐2 (BMP) to the composite. The bone formation was assessed by rat subcutaneous implantation of 4 different kinds of implants, i.e., HA alone, BMP/HA composites, MSCs/HA composites, and the composites containing BMP (MSCs/BMP/HA). Both HA and the BMP/HA composites did not show bone formation at any time after implantation. The MSCs/HA composites showed moderate bone formation at 4 weeks and extensive bone formation at 8 weeks. The MSCs/BMP/HA composites showed obvious bone formation together with active osteoblasts at 2 weeks and more bone formation at 4 and 8 weeks. The MSCs/BMP/HA composites demonstrated high alkaline phosphatase and osteocalcin expression at both the protein and gene levels. These results indicate that the combination of MSCs, porous HA, and BMP synergistically enhances osteogenic potential and provides a rational basis for their clinical application in bone reconstruction surgery.